What are the recommended pharmacologic options for treating agitation, aggression, anxiety, depression, and insomnia in adults aged 65 years and older?

Medications for Geriatric Behavioral Symptoms

For severe agitation in older adults, prioritize nonpharmacologic approaches first, but when medications are necessary, use oral quetiapine at the lowest effective dose, avoiding benzodiazepines entirely except for alcohol/benzodiazepine withdrawal. 1

Agitation and Aggression

First-Line Approach

• Always attempt nonpharmacologic interventions first (person-centered communication, sensory therapy, environmental modifications) as serious adverse events occurred in 16.8% of older adults receiving antipsychotic or anxiolytic medications 1

When Medications Are Required

Oral medications are strongly preferred:

• Oral quetiapine demonstrated the best safety profile among all studied medications for severe agitation 1
• Oral formulations are less coercive and significantly safer than parenteral routes 1

Critical medication warnings:

• Avoid midazolam completely - it posed elevated risk of serious adverse events without any efficacy gains, and actually required more redosing 1
• Avoid benzodiazepines generally per American Geriatrics Society Beers Criteria, except for documented alcohol or benzodiazepine withdrawal 1
• Never co-administer antipsychotics with benzodiazepines in older adults 1

Dosing principles:

• Start with the lowest effective dose - higher doses of lorazepam showed significantly increased adverse events, with similar dose-response signals for droperidol and quetiapine 1
• Older adults require greater tolerance of time-to-sedation to reduce adverse events and over-sedation 1

If parenteral medication is absolutely necessary:

• Ziprasidone showed favorable safety (0/17 adverse events) but has limited data 1
• Avoid intramuscular/intravenous routes when possible - they significantly increase adverse drug events compared to oral administration 1

Common Pitfalls

The diagnostic differential matters - hyperactive delirium, intoxication, dementia-related behaviors, and psychosis each have different optimal approaches, but in undifferentiated severe agitation requiring immediate intervention, the safety hierarchy above applies 1

Insomnia

For insomnia in older adults, cognitive behavioral therapy for insomnia (CBT-I) is the gold standard, but when pharmacotherapy is needed, use low-dose doxepin, melatonin, ramelteon, or dual orexin receptor antagonists. 2

Treatment Hierarchy

First-line:

• Cognitive behavioral therapy for insomnia provides longer-term sustained benefit and is more effective long-term than medications 3
• Combination therapy (behavioral + pharmacologic) may provide better short-term outcomes than either alone, with behavioral therapy sustaining improvements over time 3

Pharmacologic options when necessary:

• Low-dose doxepin
• Melatonin or ramelteon (melatonin receptor agonist) - no significant abuse potential or motor/cognitive impairment demonstrated 3
• Dual orexin receptor antagonists 2

Medications to avoid:

• Benzodiazepines - risks outweigh benefits in older adults due to increased sensitivity, reduced clearance, and adverse effects 3
• Antihistamines, antipsychotics, anticonvulsants - no systematic evidence for effectiveness and risks outweigh benefits 3
• Trazodone has limited published data despite frequent clinical use 3, 4

Key Considerations

• Insomnia in older adults is most often comorbid with medical and psychiatric illness 3
• Benzodiazepine receptor agonists (nonbenzodiazepines like zolpidem) have lower frequency and severity of adverse effects than older benzodiazepines, but adverse effects can still be problematic 3
• Older adults are at greater risk for adverse effects due to reduced clearance and increased sensitivity to peak drug effects 3

Depression

For depression comorbid with insomnia, use bedtime dosing of sedating antidepressants: mirtazapine, nefazodone, or tricyclic antidepressants, though side effects may limit usefulness. 4

Treatment Approach

• When insomnia is comorbid with mild-to-moderate depression, sedating antidepressants at bedtime are preferred 4
• Citalopram can be effective for agitation in dementia patients, but monitor QT interval prolongation 5
• SSRIs and SNRIs are guideline-recommended but underutilized in primary care settings 6

Anxiety

For anxiety in older adults, avoid benzodiazepines; consider SSRIs/SNRIs as first-line pharmacotherapy when nonpharmacologic approaches are insufficient. 6

Critical Points

• Benzodiazepines were overprescribed (55.9-69.6%) in patients with anxiety and insomnia despite not being guideline-recommended 6
• Agitation-anxiety features in depression define a more severe phenotype requiring more intensive treatment 7

Dementia-Related Agitation

For agitation in dementia, identify triggers and use environmental modifications first; if pharmacotherapy is needed, brexpiprazole has the strongest evidence and most favorable safety profile, followed by risperidone or aripiprazole with careful monitoring. 8

Treatment Algorithm

1. Nonpharmacological interventions first: trigger identification, environmental adjustments, supportive activities 8
2. Consider acetylcholinesterase inhibitors and memantine to enhance cognition 5
3. If insomnia/sundowning present: trazodone 5
4. If agitation persists:
   • Brexpiprazole (strongest evidence, best safety profile) 8
   • Citalopram (monitor QT interval) 5, 8
   • Low-dose atypical antipsychotics (risperidone or quetiapine) with disclosure of cerebrovascular and extrapyramidal risks 5, 8

Important Warnings

• Long-term or routine pharmacological use is not supported by evidence 8
• Anticonvulsants have limited efficacy and should be reserved for refractory cases 8
• Risperidone and aripiprazole require careful monitoring for cerebrovascular and extrapyramidal risks 8